Fax: (617) 726-9414
Annual screening strategies in BRCA1 and BRCA2 gene mutation carriers†
A comparative effectiveness analysis
Version of Record online: 20 SEP 2011
Copyright © 2011 American Cancer Society
Volume 118, Issue 8, pages 2021–2030, 15 April 2012
How to Cite
Lowry, K. P., Lee, J. M., Kong, C. Y., McMahon, P. M., Gilmore, M. E., Cott Chubiz, J. E., Pisano, E. D., Gatsonis, C., Ryan, P. D., Ozanne, E. M. and Gazelle, G. S. (2012), Annual screening strategies in BRCA1 and BRCA2 gene mutation carriers. Cancer, 118: 2021–2030. doi: 10.1002/cncr.26424
A portion of this work was presented in abstract form as an oral presentation at the 96th Scientific Assembly and Annual Meeting of the Radiological Society of North America; November 28 to December 3, 2010; Chicago, IL.
- Issue online: 6 APR 2012
- Version of Record online: 20 SEP 2011
- Manuscript Accepted: 20 JUN 2011
- Manuscript Revised: 10 JUN 2011
- Manuscript Received: 15 APR 2011
Vol. 118, Issue 21, 5448, Version of Record online: 20 MAR 2012
- BRCA1 gene;
- BRCA2 gene;
- breast neoplasms;
- mass screening;
- computer simulation
Although breast cancer screening with mammography and magnetic resonance imaging (MRI) is recommended for breast cancer-susceptibility gene (BRCA) mutation carriers, there is no current consensus on the optimal screening regimen.
The authors used a computer simulation model to compare 6 annual screening strategies (film mammography [FM], digital mammography [DM], FM and magnetic resonance imaging [MRI] or DM and MRI contemporaneously, and alternating FM/MRI or DM/MRI at 6-month intervals) beginning at ages 25 years, 30 years, 35 years, and 40 years, and 2 strategies of annual MRI with delayed alternating DM/FM versus clinical surveillance alone. Strategies were evaluated without and with mammography-induced breast cancer risk using 2 models of excess relative risk. Input parameters were obtained from the medical literature, publicly available databases, and calibration.
Without radiation risk effects, alternating DM/MRI starting at age 25 years provided the highest life expectancy (BRCA1, 72.52 years, BRCA2, 77.63 years). When radiation risk was included, a small proportion of diagnosed cancers was attributable to radiation exposure (BRCA1, <2%; BRCA2, <4%). With radiation risk, alternating DM/MRI at age 25 years or annual MRI at age 25 years/delayed alternating DM at age 30 years was the most effective, depending on the radiation risk model used. Alternating DM/MRI starting at age 25 years also produced the highest number of false-positive screens per woman (BRCA1, 4.5 BRCA2, 8.1).
Annual MRI at age 25 years/delayed alternating DM at age 30 years is probably the most effective screening strategy in BRCA mutation carriers. Screening benefits, associated risks, and personal acceptance of false-positive results should be considered in choosing the optimal screening strategy for individual women. Cancer 2012. © 2011 American Cancer Society.